retatrutide fda approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and What Is Retatrutide? New Weight

Current standard of care for obesity-related KOA is: NSAIDs (symptom relief, doesn't address the cause, significant GI/cardiovascular risks long-term) Corticosteroid injections (short-term, diminishing returns, potential cartilage damage with repeated use) Hyaluronic acid injections (evidence is mixed, effects modest) Physical therapy (beneficial but limited when weight load isn't addressed) Total knee replacement (effective but major surgery, significant recovery, not without long-term complications) Retatrutide at TRIUMPH-4 doses addresses both the cause (adiposity, inflammation) and the symptoms (pain), with a safety profile that compares favorably to chronic NSAID use or surgical intervention

Watch: GLP-1 and lifestyle considerations Published research cited in this article Wang W, Volkow ND, Berger NA, et al

Primary and secondary cardiovascular disease prevention interventions targeting lifestyle risk factors in women: A systematic review and meta-analysis

Benefits of Semaglutide include: Can help you lose 15% or more of your body weight Can improve heart health and prevent cardiovascular complications Can boost your metabolism Prevents overeating & unhealthy snacking Can lower your blood glucose level Can create an overall healthier lifestyle These benefits can be life-changing and help you establish a healthier lifestyle

It blocks the action of the DPP-4 enzyme

It was subsequently found by Ellis Samols and Vincent Marks in 1966 [21] and confirmed by others that glucagon-like immunoreactivity was also present in extra-pancreatic tissues, in particular in the intestine [[22], [23], [24], [25], [26], [27]]